Seagen vs. Daiichi Sankyo marks a major setback for broad biologics genus claims as the Federal Circuit overturned Seagen’s $41.8M jury verdict, invalidating US10808039B2 for lack of written description and enablement under the post Amgen v. Sanofi standard.
In the case Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating claims related to Merck’s multiple sclerosis drug Mavenclad, an oral formulation of the compound Cladribine. Merck Serono S.A. v. Hopewell Pharma Ventures, Inc. – Basic Details: Merck Serono S.A. v. Hopewell Pharma … Read more
